AI-generated content for informational purposes only. Not financial advice. Always do your own research.

关于

Tracks US investment-grade corporate bonds, providing higher yields than Treasuries with moderate credit risk. Popular income-generating fixed income ETF.

债券与固定收益

LQD 跟踪美国投资级公司债券,相比国债提供更高收益率,具有中等信用风险,适合作为专注收入投资组合的核心固定收益持仓。

Key Financials LQD

价格 $111.59
变化(1天) +0.33%
变化 (30D) +1.27%
变化 (60D) +1.15%
变化 (90D) +0.36%
变化 (180D) +4.31%
变化 (1Y) +4.54%
变化 (5Y) -17.44%
P/E比率 16.46
EPS (TTM) $6.78
52周区间 $103.45 — $112.93
50日MA $110.59
成交量 33.61M

Data updated Feb 15 · Source: Twelve Data

4.2
1 reviews
Fundamentals
4.3
Management Quality
4.3
Valuation
4.2
Performance
4
Risk Profile
3.8
Claude Opus 4.6
AI Review
4.2/5

iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD) is the flagship investment-grade corporate bond ETF and a cornerstone holding for fixed-income investors. With over $30 billion in assets and exceptional liquidity (33.6M average volume), LQD offers efficient exposure to a diversified basket of USD-denominated investment-grade corporate bonds.

The fund has recovered meaningfully from its 2022-2023 lows, trading near its 52-week high at $111.59, reflecting improved sentiment as rate hike cycles wind down. The 4.54% one-year return signals stabilization, though the -17.44% five-year decline underscores the duration risk that punished bondholders during the rate-rising cycle.

Bull case: Attractive yields at current levels, potential for capital appreciation if rates decline, and strong credit quality provide a solid income foundation. Bear case: Duration risk remains elevated (~8-9 years), credit spreads are historically tight offering limited cushion, and persistent inflation could delay rate cuts.

LQD remains a high-quality core fixed-income allocation, best suited for investors seeking steady income with moderate interest rate sensitivity. The tight credit spreads warrant monitoring but overall fundamentals support the position.

Fundamentals
4.3
Management Quality
4.3
Valuation
4.2
Performance
4
Risk Profile
3.8
Feb 15, 2026